A LIFETIME OPP on this stock guys :
SNOA =Market-Cap $19 M /Cash balance $12.6 M /Shares Out 4.3 M / UNKNOWN Stock/ 17 FDA approvals received to date some of these products are in early launch phase plus additional Product launches expected within 6 months in USA and many more Approvals outside of USA // Annual Revenue on track to hit $16 million// Profitability expected in 2018 . This unknown ultra low float and brutally undervalued stock is a MUST HAVE for everyone who like Pharma stocks .GL
Sonoma Pharma (Nasdaq: SNOA)
Marketcap: 19.6 Million
Cash: $12.6 Million
Price: $4.55
Book Value: $4.32
Annual Revenue on track to hit $16 Million
Shares Out : 4.3 Million
Analysis by Stonegate
http://pr.report/78EFCjq0
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
•Mondoxyne for severe acne –launched late 2015
•Ceramax for skin repair in atopic dermatitis–launched in April 2016
•SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017
•Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Regulatory Approvals and Clearances
To date, we have obtained 17 clearances from the U.S. Food and Drug Administration, or FDA, that permit us to sell our products as medical devices for Section 510(k) of the Federal Food, Drug and Cosmetic Act in the United States.
Outside the United Sates, we sell products for dermatological and advanced tissue care with a European Conformity marking (known as Conformité Européenne or CE) covering 25 of our products, and various approvals in Central America, China, Southeast Asia, and the Middle East.
SNOA =Market-Cap $19 M /Cash balance $12.6 M /Shares Out 4.3 M / UNKNOWN Stock/ 17 FDA approvals received to date some of these products are in early launch phase plus additional Product launches expected within 6 months in USA and many more Approvals outside of USA // Annual Revenue on track to hit $16 million// Profitability expected in 2018 . This unknown ultra low float and brutally undervalued stock is a MUST HAVE for everyone who like Pharma stocks .GL
Sonoma Pharma (Nasdaq: SNOA)
Marketcap: 19.6 Million
Cash: $12.6 Million
Price: $4.55
Book Value: $4.32
Annual Revenue on track to hit $16 Million
Shares Out : 4.3 Million
Analysis by Stonegate
http://pr.report/78EFCjq0
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
•Mondoxyne for severe acne –launched late 2015
•Ceramax for skin repair in atopic dermatitis–launched in April 2016
•SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017
•Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Regulatory Approvals and Clearances
To date, we have obtained 17 clearances from the U.S. Food and Drug Administration, or FDA, that permit us to sell our products as medical devices for Section 510(k) of the Federal Food, Drug and Cosmetic Act in the United States.
Outside the United Sates, we sell products for dermatological and advanced tissue care with a European Conformity marking (known as Conformité Européenne or CE) covering 25 of our products, and various approvals in Central America, China, Southeast Asia, and the Middle East.
